Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.
You may also be interested in...
Nordic Nanovector In Limbo As Merger Collapses
The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
How Nordic Nanovector Stepped Back From The Abyss With APIM Merger
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO
Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback.